Safety and Efficacy of the Gore® Excluder® Iliac Branch Platform and Analysis of Its Behavior in Combination With the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (IBERVIX)

Aortic Aneurysm Clinical Trial

— IBERVIX  

Official title:

Seguridad y Eficacia de la Plataforma Gore® Excluder® Iliac Branch y análisis de su Comportamiento en Combina-ción Con la Endoprótesis GORE® VIABAHN® VBX Ba-lloon Expandable

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04356313
• Other study ID #: AEEVGalicia
• Status: Recruiting
• Start date: October 1, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: April 2020
• Source: Asociacion para el Estudio de la Enfermedades Vasculares de Galicia
• Contact: Jorge Fernández Noya, M.D
• Phone: +34629550241
• Email: jfernoy[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aorto-iliac aneurysms with involvement of the iliac bifurcation or hypogastric artery aneurysms constitute only 20% of all aneurysmal pathology of the abdominal aorta. As it is a rare pathology, in order to carry out a comprehensive study of the results, it is necessary to carry out multicenter studies to collect a considerable number of cases.

One of the most widely used devices worldwide is the GORE® EXCLUDER® Iliac Branch Endoprosthesis, CE marked since 2013, this stent consists of two components: the iliac branch stent and the hypogastric component (HGB), for its joint use there are instructions for use in relation to the anatomical characteristics of the patient in order to be used.

Currently, there are other devices that can be used as a hypogastric component when the patient's anatomy does not allow the use of HGB, one of them is: GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, CE marked since 2017.

This study is designed to evaluate the efficacy and safety of devices with iliac branches for the treatment of aorto-iliac aneurysms that affect the bifurcation of common iliacs, with the use of these devices, as well as to determine the quality of life of patients after their implantation.

Description:

This is a multicenter study in which 10 to 15 hospitals will participate. It is a non-intervention study in which the data from the medical records of the patients will be collected according to the action protocols of each center.

This is a prospective, non-randomized study where the data of the implants performed during a 12-month period will be recorded. Both the diagnosis and the follow-up of the patients to whom the device is implanted will strictly adhere to the protocols present in each center and which are the ones used according to all current clinical guidelines. At no time will any intervention or diagnostic test be performed outside the protocols in force in each center. The study does not imply any intervention or visit for the participants that is not routine clinical practice according to the clinical-healthcare procedures of each participating center.

Following routine clinical evaluations performed as part of standard patient care, it will be decided, after obtaining informed consent from patients, and whether they are eligible for the study and scheduled for the implant procedure with the devices. of the study.

After a baseline evaluation, the implant will be performed according to the usual clinical practice of each participating center. A follow-up visit will be made 30 days, 6 and 12 months after the procedure.

Investigators will perform implant and device evaluations and document adverse events (AE) and possible device deficiencies

Study objectives

1. Primary Objectives 1.1. General safety and efficacy at 6 months post-implant

Defined as :

• Absence of symptoms or rupture of the aneurysm.

• Growth of the aneurysm.

• Absence of reintervention.

• Need for conversion to open surgery.

• Significant clinical migration.

• Branch occlusions.

1.2 Technical success: GORE® Excluder® IBE implant in the planned location. No conversion, death, type I or III endoleaks or obstruction of the extremity of the graft.

1.3. Safety and efficacy of IBE together with VBX compared to IBE all-in-one system at 6 months.

2 Secondary objectives 2.1. Absence of major adverse effects defined as:

• Absence of morbidity and / or mortality related to the aneurysm or the device.

• Absence of mortality from any cause.

2.2. Assessment of quality of life based on the EuroQol 5D questionnaire

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who have an aortoiliac aneurysm with criteria to be operated electively and who meet the anatomical criteria to be treated with the devices under study within the instructions for use.

Exclusion Criteria:

• Patients who, given their anatomical characteristics, do not comply with the instructions for use of the devices under study.

• Patients with pathology at the iliac level but not aneurysmal.

• Patients who do not sign the informed consent to participate in the study

Related Conditions & MeSH terms

• Aneurysm
• Aortic Aneurysm
• Iliac Aneurysm

Intervention

Device:
• GORE® EXCLUDER® Iliac Branch Endoprosthesis
Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component

Locations

Country	Name	City	State
Spain	University Clinical Hospital	Santiago De Compostela	A Coruña

Sponsors (2)

Lead Sponsor	Collaborator
Asociacion para el Estudio de la Enfermedades Vasculares de Galicia	W.L.Gore & Associates

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	General safety and efficacy at 6 months post-implant	Absence of symptoms or rupture of the aneurysm. Growth of the aneurysm. Absence of reintervention. Need for conversion to open surgery. Significant clinical migration. Branch occlusions	6 months
Primary	Technical success	GORE® Excluder® IBE implant in the planned location. No conversion, death, type I or III endoleaks or obstruction of the extremity of the graft.	1 year
Primary	Safety and efficacy	IBE together with VBX compared to IBE all-in-one system	6 months
Secondary	Absence of major adverse effects	Absence of morbidity and / or mortality related to the aneurysm or the device. Absence of mortality from any cause.	6 months
Secondary	Assessment of quality of life	Based on the EuroQol 5D questionnaire	6 months